US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock article: Follicum a step closer to phase II

BioStock published an article on 21 October 2019 about Follicum, which can be read in full below. Today, news broke that Follicum had completed the supplementary toxicology studies that will form the basis for the upcoming phase II trial with their topical formulation of FOL-005. The study results were positive, safeguarding the company’s expectation to initiate the clinical study in early 2020.When the peptide company Follicum  announced positive results from supplementary toxicology studies today, it took a further step on the road to clinical phase II with the

BioStock-article: FOLLICUM IS CLOSING IN ON PROOF-OF-CONCEPT FOR HAIR LOSS PRODUCT

BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer and closer to realising its business model.Follicum  develops pharmaceutical drugs with First-in-Class potential, i.e., completely new treatment concepts with unique mechanisms of action within the field of stimulation

Interview with Mats Persson, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum?I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from senior positions at Astellas Pharma Norden/Baltic (CEO), Novo Nordisk, Pharmacia Corporation and Ferring International.  I am also a Board Member of Gedea Biotech AB as well as Nordic Rebalance a/s and I own MS Persson Consulting AB where I support Companies

Endpoints News article about Follicum

On 27 February 2019, Endpoints News published an article about Follicum: “Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs”.Read the article  For further information, please contact:Jan Alenfall – CEO, Follicum ABTelephone: +46 46 19 21 97Email: info@follicum.com About Follicum ABFollicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary

Article in BioStock: Follicum have developed a creamlike formulation for treatment of hair loss

BioStock published an article about Follicum’s topical formulation on 7 February 2019 in Swedish . The article is here translated into English. Follicum develops FOL-005 to stimulate hair growth. The peptide-based candidate has recently undergone a phase IIa-study and the company was able to present positive top-line results during the fall. This summer a topical formulation of FOL-005 was completed and the company have now presented results demonstrating that treatment with the

Interview Follicum: The results are very exciting and motivate us to start a topical study

BioStock (www.biostock.se) 2018-11-01 – Translation from Swedish languageYesterday, Follicum presented top-line results from the First-In-Man scalp study with FOL-005 for stimulation of hair growth. The results confirm that the treatment is well tolerated and show that FOL-005 has the capacity to stimulate hair growth at optimal dosage. BioStock contacted the company's CEO, Jan Alenfall, for further comments about the study and the results, what they mean and what the next step for Follicum will be. Follicum's primary candidate, FOL-005, is developed to stimulate hair growth. A first

Interview with Jonas Edelswärd, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum?I have more than 25 years of experience from various positions in high-tech start-up companies, particularly from the innovation environments around Lund University and Malmö University, Ideon Innovation and MINC incubator.  I have also worked with more mature companies, such as CEO for the privately held investment company AB Axel Granlund in Malmö for 8 years. I have extensive experience in evaluating small and medium-sized enterprises in various stages of development, particularly from when I was a business

Follicum featured in the June issue of The New Yorker: “Is the Age-Old Quest for a Baldness Cure Reaching Its End?”

Amos Barshad writes about baldness and the development of tentative cures and Follicum is among the companies mentioned in the article.“In Sweden, a company called Follicum is now doing Phase IIA clinical studies and planning to communicate results by the end of the year. The end product will be a cream or a lotion, one that could be applied as few as three times a week. In the first trial, Follicum claims, more than seventy-five per cent of patients experienced hair growth. This is the real dream, the one so artfully captured in the Hims ads: pop a pill, slap on some cream, and get Hair

There are no items matching the current filter
There are no more items matching the current filter
Back to top